OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	370
Prioritising health equity alongside donation safety – Authors' reply	297
Zanubrutinib-associated ecchymotic lesions	206
In the trenches	178
Correction to Lancet Haematol 2024; 11: e114–26	176
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	154
Correction to Lancet Haematol 2023; 10: e333–45	142
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	136
MRD-guided treatment cessation in multiple myeloma	125
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	123
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	120
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	118
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	109
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	94
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	94
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	94
Bedside art is good medicine	93
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	93
Artwork from trauma: the social life of medical data	85
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	80
Be compliant or compromise?	78
International Society on Thrombosis and Haemostasis Congress 2023	76
Blood cell defence against pathogens	74
Blood deserts: a vision to tackle blood inaccessibility	72
Rituximab versus active surveillance in patients with follicular lymphoma	71

Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	70
Correction to Lancet Haematol 2023; 10: e433–44	70
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	69
Production and supply of blood products in Brazil	66
Anaemia in a time of climate crisis	65
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	65
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	65
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	65
Extensively distributed erythema nodosum in VEXAS syndrome	63
USAID's enduring impact on anaemia management must be preserved	62
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	61
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	59
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	59
Sickle cell disease in India: current status and progress	58
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	56
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	56
Correction to Lancet Haematol 2025; 12: e294–303	56
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	55
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	55
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	55
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	54
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	53
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	52
Universal health coverage for children with cancer	52
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	51
Could improving mental health disorders help increase cancer survival?	51